Genflow Completes Dosing Phase of Canine Gene Therapy Trial
Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a biotechnology company focused on extending healthspan through advanced gene therapies, today announced that all dogs enrolled in its ongoing clinical trial have successfully received the full administration of the Company's investigational SIRT6-based gene therapy. Importantly, no adverse events were reported during the dosing phase of the study. No serious,...
Read more









